Logo
Menu

Delivering a complete colorectal cancer solution for you and your patients

Trust the experts with over 20 years of experience. 

Tests & services
Tests & services

Colorectal cancer is the fourth most common type of cancer in the United States.1
One in 24 people will be diagnosed with colorectal cancer in their lifetime.2

The NeoGenomics colorectal cancer solution supports the care continuum with tests that detect genomic alterations relevant to diagnosis, therapy selection, prognosis, and clinical trial options.

Featured colorectal cancer solutions

NEO PanTracer Tissue (formerly Neo Comprehensive - Solid Tumor)

NGS comprehensive genomic profile targeting 517 genes in DNA and RNA for SNVs, InDels, CNVs, RNA fusions/splice variants with MSI and TMB for pan-solid tumors.

8-10 Days turnaround time

Learn more about this test

Comprehensive testing for colorectal cancer patients

Over half of advanced-stage colorectal cancer patients have an actionable alteration, the most common being KRAS and NRAS mutations.3 Genomic biomarker testing plays a crucial role in guiding precision medicine for patients with metastatic colorectal cancer with several FDA- approved targeted and immuno-therapy options.

PanTracer Tissue covers key biomarkers recommended by clinical practice guidelines. ​

As the treatment landscape for colorectal cancer becomes increasingly complex, PanTracer simplifies treatment planning, removing guesswork and uncertainty enabling you to treat confidently.

Guideline-driven biomarker detection for colorectal cancer4-7

colorectal biomarkers

MSI, microsatellite instability.

Add-on testing for therapy selection

Mismatch Repair (MMR) IHC Panel

Global: 2 Days, Image Analysis (Tech-only): 2 Days, Tech-Only (stain only): 1 Day turnaround time

Learn more about this test

HER2 (Other)

Global: 2 Day, Tech-Only (stain only): 1 Day turnaround time

Learn more about this test

References

  1. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: colorectal cancer. Accessed December 23, 2024. https://seer.cancer.gov/statfacts/html/colorect.html

  2. Colorectal Cancer Alliance. Colorectal cancer facts and statistics. Accessed December 23, 2024.
    https://colorectalcancer.org/basics/facts-and-statistics

  3. Saeed O, Lopez-Beltran A, Fisher KW, et al. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. J Clin Pathol.2019;72(2):135-139. 

  4. Yu IS, Aubin F, Goodwin R, et al. Tumor biomarker testing for metastatic colorectal cancer: a Canadian consensus practice guideline. Ther AdvMed Oncol. 2022;14:17588359221111705.

  5. Hollasch M. Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies. Oncol Live. 2024;25(16).

  6. Cherri S, Oneda E, Zanotti L, Zaniboni A. Optimizing the first-line treatment for metastatic colorectal cancer. Front Oncol. 2023;13:1246716.

  7. Chakravarty D, Johnson A, Sklar J, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinicalopinion. J Clin Oncol. 2022;40(11):1231-1258.

Still have questions?

We pride ourselves on our unparalleled Client Services team. If you have questions regarding test information, specimen requirements, turnaround times, test add-ons, or patient results, please email us at client.services@neogenomics.com or call 866.776.5907, Option 3.